Population Pharmacokinetics and Dose Optimization of Valganciclovir and Ganciclovir in Lung Transplant Recipients.

ABSTRACT:

Objective

The primary goal of this study was to evaluate the pharmacokinetics (PK) of ganciclovir (GCV) and its prodrug valganciclovir (VGCV) in a large cohort of lung transplant recipients. The secondary goal was to determine the probability of target attainment (PTA) for different pharmacokinetic/pharmacodynamic (PK/PD) targets.

Subjects and methods

A population PK analysis was carried out using NONMEM version 7.4.0. In total, 379 GCV concentrations (194 and 185 concentrations sampled after VGCV and GCV administration, respectively) were obtained from 110 patients and were included in the analysis. Monte Carlo simulations were performed to assess PTA for (AUC_24h) >50 mg·h/L and AUC_24h of 80-120 mg·h/L.

Results

Estimated glomerular filtration ra

SUBMITTER: Dvorackova E 

PROVIDER: S-EPMC12707957 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature